Liver Cancer News
Click on the title to read the rest of the Liver Cancer News story.
20,000 Vietnamese Die Of Liver Cancer Each Year
27 June 2018
Vietnam has a population of 95 million people. The cited reasons for the liver cancer death rate is due to “late diagnosis and treatment.”
Better Buy: Exelixis, Inc. Vs Immunogen, Inc.
26 June 2018
The cancer drug Cabozantinib, created by Exelixis, Inc. is going under an FDA review in the hopes of getting the drug extended to treat liver cancer. Cabozantinib is a pill that was originally created for treatment of kidney cancer.
Son Of Cream Legend Jack Bruce Hails His Dad’s Genius And Reveals Special Plans To Celebrate Band’s Legacy
25 June 2018
Jack Bruce was diagnosed with liver cancer in 2003 and was not expected to survive long-term. He reunited with two members of his band Cream in Albert Hall in 1968 and had a 50th Anniversary World Tour. Jack’s son is now celebrating his father’s legacy.
Allan Ralph Cooper Dies
25 June 2018
Allan Cooper passed away from his battle with liver cancer on June 17th, 2018 in Truckee, CA. He was a member of the US Army for 3 years and worked for the Continental Federal Credit Union for 33 years. He has surgery to remove a portion of his liver but was unable to pull through with the remaining portion of his liver.
Perioperative Antivirals Reduce HBV Reactivation After Transarterial Chemoembolization
25 June 2018
For HCC patients, taking antiviral therapy before getting transarterial chemoembolization (TACE) may improve liver function. This new research is an exciting step forward in the treatment of Hepatocellular Carcinoma.
These Symptoms, Pointing to Liver Cancer The Chronicle of World Events
25 June 2018
According to the British organization Cancer Research UK, potential signs of liver cancer are: a loss of appetite and weight that can’t be identified, swelling of belly, and nausea.
Benefits Of Coffee
23 June 2018
The antioxidants in coffee have been linked to a lowered risk of liver cancer. Specifically, caffeinated coffee has a benefit in reducing cancer risk.
Global Hepatocellular Carcinoma (HCC) Epidemiology Forecast To 2027, With Coverage Of 8 Major Markets Including United States, EU5 Countries, China & Japan
22 June 2018
The research in this report shows that the total number of incident cases for HCC in G8 countries in 2016 was 458,170.
Levantinib-Pembrolizumab Shows Promise In Several Cancer Types
22 June 2018
There is current research in the use of Levantinib (Lenvima, Eisai) and Pembrolizumab (Keytruda, Merck) for patients with Hepatocellular Carcinoma, renal cell carcinoma, endometrial cancer, and head and neck cancers. The advance of these research trials is bringing hope to patients.
Dr. Finn Recaps Second-Line Advancements In HCC
22 June 2018
In the last year and a half, ‘there have been many advancements in the management of patients with advanced HCC’. The two medications that have shown positive results are Stivarga and Lenvima.
Resveratrol And Cancer
22 June 2018
It is difficult for humans to absorb but Resveratrol is a polyphenol (antioxidant) that has been shown to have anti-cancer effects. The compound can be found in grapes, red wine, berries and peanuts.
NCCN Offers New Resource For Patients With Hepatobiliary Cancers
21 June 2018
The National Comprehensive Cancer Network (NCCN) is releasing a new edition of their guidelines for patients with liver, gallbladder, and bile duct cancers. This is to assist patients with more information to understand their treatment decisions.
B.C. Transplant May Accept Hepatitis C Positive Donors Now That There’s A Curative Drug Treatment For Recipients Who Contract It
21 June 2018
Because of the drugs that are able to cure hepatitis C, doctors such as Dr. David Landsberg are beginning trials that transplant organs from Hep C patients to patients who are in need of a transplant to survive.
Adding SIRT Does Not Provide Survival Benefit In Advanced HCC, Except In Select Patients
20 June 2018
In patients with advanced Hepatocellular Carcinoma, Selective internal radiation therapy (SIRT) in combination with Nexavar does not significantly improve survival in comparison to solely taking Nexavar. But there is a subgroup of patients who may find a benefit in this combination therapy.
Hardiwar-Based Scientist Claimed Herbal Breakthrough for Hepatocellular Carcinoma
13 June 2018
Dr. Hemanth is studying a new pathway to treat Hepatocellular Carcinoma and is planning to patent the pathway and natural drugs that lower AFP (alpha-fetoprotein). Because Hepatocellular Carcinoma is considered ‘highly chemo-resistant’, finding this new pathway may be a beneficial new approach to treating the cancer.
Merck KGaA Give A Good Hint Of Efficacy In A Special Form Of Liver Cancer
13 June 2018
For patients with advanced Hepatocellular Carcinoma, there are positive results from two phase-2 clinical trials done by Merck. The drug Tepotnib, is being used as first-line and second-line treatment for tumors that have the gene MET mutation.
Celsion Corporation: A Summer Of Catalysts
12 June 2018
The Optima Trial is a phase 3 trial for lung cancer patients. The company Celsion expects to have complete enrollment of 550 patients by the end of the summer. This is good news for the Celsion, as their previous study ThermoDox did not have success as standardized heat treatment for patients.
Using Cell-Free DNA As A Marker For Liver Cancer Diagnosis
1 June 2018
Dr. Kang Zhang is interviewed about his diagnostic work at the Laboratory for Advanced Medicine (LAM). He is a geneticist and a physician who is looking at a very specific area of DNA to identify liver cancer.
Inspyr, Lewis And Clark Merge With Prodrug And Adenosine Receptor Modulator Pipeline
31 May 2018
Inspyr Therapeutics and Lewis and Clark Pharmaceuticals have entered into a merger. Now combined, development of Inspyr’s mid-clinical-stage anticancer prodrug therapeutic mipsagargin will continue. Mipsagargin has undergone a Phase II study in patients with Nexavar® (sorafenib) as a treatment for Hepatocellular Carcinoma (HCC) and has been granted FDA orphan drug designation for the HCC indication.
Polaris Group Announces Treatment Of First Patient In A Phase 2 Study Of ADI-PEG 20 Plus Gemcitabine And Docetaxel For Soft Tissue Sarcoma
30 May 2018
Polaris Group has treated their first patient in a phase 2 trial of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma, sponsored by Washington University. Polaris is also conducting a global phase 2/3 study in malignant plural mesothelioma featuring ADI-PEG 20 in combination with pemetrexed and cisplatin and a global phase 2 study in Hepatocellular Carcinoma (HCC) featuring ADI-PEG 20 in combination with FOLFOX. ADI-PEG 20 is a biologic being developed to treat cancers carrying a major metabolic defect that renders them unable to internally synthesize arginine.
Resection May Be Underused For Stage I Liver Cancer, Researchers Say
30 May 2018
According to a matched-cohort study presented at the 2018 Society of Surgical Oncology Annual Cancer Symposium, patients with stage I Hepatocellular Carcinoma (HCC) of 5 cm or less experienced greater overall survival, when compared with radiofrequency ablation. The study was conducted by Dr. Newton and his colleagues, using the National Cancer Data Base (NCDB) Liver 2004 – 2014 Participant User File. The study cohort included 34,971 patients with clinical stage I HCC. “Hepatic resection for small solitary HCC may be underutilized in the United States, considering so many patients with small and intermediate-size tumors are receiving RFA and not resection,” Dr. Newton said.
FDA Accepts Cabometyx Drug Application For Advanced HCC
30 May 2018
The FDA has accepted a supplemental new drug application for Cabometyx tablets as a treatment for patients with previously treated advanced Hepatocellular Carcinoma created by Exelixis. “Patients with this aggressive form of advanced liver cancer urgently need new treatment options after they progress on first-line therapy,” Gisela Schwab, MD, president of product development and medical affairs and chief medical officer at Exelixis. Cabometyx (cabozantinib) previously received approval to treat patients with renal cell carcinoma. Exelixis submitted the supplemental new drug application for HCC in March 2018 based on top line results from a phase 3 study.
Exelixis Announces U.S. FDA Accepts sNDA For CABOMETYX In Previously Treated Advanced Hepatocellular Carcinoma
29 May 2018
The U.S. Food and Drug Administration (FDA) has accepted the filing of Exelixis’s supplemental New Drug Application (sNDA) for CABOMETYX® (cabozantinib) tablets, as a treatment for patients with previously treated advanced Hepatocellular Carcinoma (HCC). An sNDA is an application to the FDA that, if approved, will allow a drug sponsor to make changes to a previously approved product label. Exelixis submitted the sNDA for the treatment of previously treated advanced HCC to the FDA in March 2018 based on results from the CELESTIAL phase 3 pivotal trial of CABOMETYX in patients with advanced HCC who received prior sorafenib.
Dawson Outlines Evolving Role Of Radiotherapy In Liver Cancers
29 May 2018
Radiation therapies such as stereotactic body radiation therapy (SBRT) currently have a role in the treatment of patients with Hepatocellular Carcinoma (HCC). Laura Dawson, MD explains, “Radiotherapy is an excellent treatment for most cancers and has a very strong role in most cancers.” HCC is very challenging in that most patients have cirrhosis and poor liver function, and most are not suitable for transplant or surgery. Radiotherapy is an excellent treatment in that situation.
Singapore: Clinical Stage Biotech Lion TCR Bags $20m From Yashang Capital
28 May 2018
Lion TCR, a biotech firm in Singapore, has raised $20 million. Lion TCR is focused on the development of T cell receptor (TCR)-T cell therapy against life-threatening viral infections and viral-related cancers. Lion TCR will also use this funding to advance its ongoing clinical trials of LioCyx, a personalized HBV specific TCR T cell therapy against Hepatocellular Carcinoma (HCC) in major hospitals in China and Singapore. LioCyx was developed by Lion TCR’s scientific founder Prof. Antonio Bertoletti and his team, along with the collaboration of Singapore General Hospital, LioCyx won the 2018 SingHealth Duke-NUS Research Award 1st Prize and the Best Abstract in EASL International Liver Congress 2018.
Homer1 Linked To Tumor Size In Hepatitis B Induced Liver Cancer
27 May 2018
Homer1 has been identified to play a role in the tumor generation of hepatitis B-induced Hepatocellular Carcinoma (HCC). A study led by Jiancheng Tu at the Zhongnan Hospital of Wuhan University investigated the expression profile, clinical, diagnostic and prognostic significance of Homer1 in hepatitis B virus-induced HCC. They found that the levels of Homer1 were both downregulated in HCC cell line and tissue and were associated with tumor size. Large-scale studies are still needed to confirm these findings.
FDA Delays Decision On Lenvatinib For HCC
25 May 2018
The FDA has extended the review period for lenvatinib (Lenvima) as a first-line treatment for patients with unresectable Hepatocellular Carcinoma (HCC), to allow ample time to review the application. The sNDA submitted for lenvatinib was based on data from the phase III REFLECT trial. According to the trial, the median overall survival (OS) with lenvatinib was 13.6 months compared with 12.3 months for sorafenib. “Based on our results, lenvatinib might be a potential new treatment option for advanced Hepatocellular Carcinoma,” said first author Masatoshi Kudo, MD, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Adding A New Dimension To Cancer
24 May 2018
Daniel Gioeli, associate professor of Microbiology, Immunology and Cancer Biology at the University of Virginia, with the collaboration of HemoShear Therapeutics was able to successfully recreate a cancer tumor environment outside of a patient’s body. Brian Wamhoff, the head of innovation at HemoShear Therapeutics, said the company is focused on developing therapies for rare diseases, primarily in the liver. A patient’s tumor can be introduced into this 3D model and customized to test the effectiveness of different drugs. This model would enable users to find medications specific to the patient, so that patients may have a better chance of responding treatment.
Some Philadelphia Researchers Are Using Microbubbles To Improve Cancer Treatments
23 May 2018
Microbubbles are now FDA approved for use in ultrasound technology and researchers are hoping they will improve cancer treatments. A treatment called radioembolization, involves depositing radioactive beads directly to the tumor. This results in cutting off the blood to the tumor. “In this trial what we’re looking at is can we use these bubbles to improve radioembolization techniques,” said Dr. John Eisenbrey. “Our early data is suggesting it’s having a pretty dramatic improvement on tumor outcomes.” The Jefferson researchers are looking to enroll more patients, and hope to use this technology to treat other cancers by filling the microbubbles with oxygen or chemotherapy.
Genoscience Pharma Extends Its First Clinical Trial Of GN561 In Patients With Advanced Liver Cancers To France
22 May 18
Genoscience Pharma, biotechnology company, has extended its first-in-human Phase 1b/2a clinical study using the oral small molecule GNS561 in advanced liver cancers, in France. GNS561 is a novel Solute Carrier Transporter (SLCT) inhibitor demonstrating potent antitumor activity against a range of human cancer cell lines, including HCC. This international Phase 1/2a study, which began in April 2018 at the Jules Bordet Institute in Brussels, Belgium, will be performed in several European countries and the United States. Professor Ghassan Abu Alfa of Memorial Sloan Kettering in New York is co-principal investigator in the United States.
Large Study Confirms Daas Protect Against HCC When Sustained Viral Response Achieved
22 May 2018
A new study which included data from 22,579 patients treated in the national Veterans Affairs health care system over a 15-month period, looked at the risk for recurrence of Hepatocellular Carcinoma (HCC) in patients who achieve sustained viral response (SVR) on DAA therapy. Analysis found that the hazard ratio (HR) for HCC was nearly five times higher for patients who had cirrhosis at the time of treatment. Researchers also reported that advanced fibrosis at the time of DAA therapy was associated with an increased risk for HCC, even among patients achieving SVR. The team concluded that longer follow-up is needed to develop definitive and individualized surveillance strategies for HCC following effective DAA therapy.
Identifying Nivolumab-Related Adverse Effects Early In Advanced HCC
21 May 2018
Nivolumab (Opdivo) has demonstrated durable tumor responses and promising survival benefits for patients with advanced Hepatocellular Carcinoma (HCC). Clinicians mush not identify and manage adverse effects (AEs) of the treatment. A study of 262 patients treated were assessed. Median duration of nivolumab treatment was 4.9 months. “Overall, select treatment-related AEs were effectively managed with the use of specific treatment algorithms, and approximately two-thirds of these resolved,” said Aralee Galway, MSN, ANP-BC, AOCNP, from Massachusetts General Hospital.
Chester Professor Leading £4m Trial To Tackle Liver Cancer At The Clatterbridge Cancer Centre
21 May 2018
A team of researchers at The Clatterbridge Cancer Centre are conducting a trial aimed at improving the survival chances of one of the deadliest types of cancer. The study called TACE-3 will involve patients with intermediate (stage B) Hepatocellular Carcinoma (HCC). The Merseyside-led research will see more than 500 liver cancer patients from around the UK and France given a unique combination of drugs to see if it extends life. The study will be funded by Bristol Myers Squibb, a pharmaceutical company. TACE, which stands for TransArterial ChemoEmbolisation, is a type of chemotherapy which is delivered directly into the blood supply.
Proton Therapy Killed Tumor In 70% Of Liver Cancer Patients
16 May 2018
Researchers from Samsung Medical Center competed a study which showed proton therapy to be an effective and safe treatment for liver cancer. Proton therapy is a radiation treatment that uses positively charged particles called protons to destroy cancer cells. A team led by Professors Park Hee-chul and Yu Jeong-il from Samsung Medical Center’s department of radiation oncology, studied 101 patients with liver cancer and received proton therapy for one year starting in January of 2016. Of the 78 patients who underwent a three-month follow up after proton therapy, around 70% of patients had their tumors completely disappear, and about 18% saw a decrease in tumor size.
Sarcopenia Predicts Tumor Recurrence Post Liver Transplantation?
16 May 2018
A group of researchers, led by Young Ri Kim, from Sungkyunkwan University School of Medicine, Seoul, Korea, found that sarcopenia appears to be one of the important host factors modulating tumor recurrence risk after living donor liver transplantation (LDLT) for advanced Hepatocellular Carcinoma (HCC). The team studied 92 patients using the Milan criteria for patients with cirrhosis and HCC who received transplants with intent to cure. The researchers found that several factors, in addition to sarcopenia, were significantly associated with HCC recurrence. The mechanism underlying the association between sarcopenia and HCC recurrence is unclear.
Radiation Segmentectomy Shows Promise For Early-State Hepatocellular Carcinoma
15 May 2018
According to a recent study radiation segmentectomy showed to be a curative-intent treatment, with comparable response rates, tumor control and survival outcomes among certain patients with early-stage Hepatocellular Carcinoma (HCC). “Cone beam CT has revolutionized our ability to perform segmental injections isolated to very small tumors, sparing the majority of normal tissue,” said Riad Salem, MD, chief of vascular interventional radiology at Northwestern University Feinberg School of Medicine. Salem and colleagues performed a retrospective study of 70 patients, of which 90% showed a response, and 59% achieved a compete response.
Oncimmune Launches Liver Cancer Biopsy Product In US
14 May 2018
Oncimmune Holdings has launched a liver cancer biopsy in the US using its EarlyCDT platform. The biopsy is the second product to be launched using the EarlyCDT platform. The biopsy is a test for Hepatocellular Carcinoma (HCC) with a specificity of 97%. Oncimmune Holdings plans to distribute a ‘kit’ version of the liver biopsy product worldwide by the end of the first quarter of 2019. Geoffrey Hamilton-Fairley, chief executive of Oncimmune, states, “Currently most HCC cases are only detected once symptoms appear … Our test, which measures autoantibodies, with exceptional specificity, can detect liver cancer in its early stages of development, giving the patient the chance of more treatment options and better prognosis”
Bioprognos Announces Oncocup Dx, A Blood Test That Can Identify Up To 30 Different Cancer Types
14 May 2018
BIOPROGNOS, with the collaboration with Quick Diagnosis Units (QDUs), announced their new version of OncoCUP Dx. OncoCUP Dx is a non-invasive, accurate, and cost-effective test specially designed for Cancer Unknown Primary diagnosis. Its technology can identify up to 30 different cancer types from a simple, quick blood test. The main diagnostic tests and final diagnosis in QDUs are normally performed within 7 days after the first visit. QDU’s objectives include early diagnosis, unnecessary hospitalization and to improve patient satisfaction.
Viagra And Many Other Drugs Were Discovered By Chance. Now Science Is Hoping To Change That
13 May 2018
Drugmakers develop new drugs to target a particular condition, but almost all drugs have “off-target activity,” with some drugs affecting several hundred genes and other biological processes, said Joel Dudley, director of the Institute for Next Generation Healthcare in New York. Viagra is just one of many repurposing successes. Last year, researchers in Butte’s lab used the computer algorithm to identify four drugs with potential for treating Hepatocellular Carcinoma (HCC).
SMYD2 Associated With Poor Prognosis In Hepatocellular Carcinoma
13 May 2018
SET and MYND domain-containing protein2 (SMYD2) are a candidate human oncogene in multiple tumors. A new study, led by Dr. Shi-Kun Liu at the Central South University in China, discovered that the SMYD2 expression in Hepatocellular Carcinoma (HCC) tissues was significantly up-regulated at both mRNA and protein levels as compared with the matched adjacent non-tumorous tissues. This study suggests that SMYD2 can serve as a promising biomarker for the early diagnosis and prognostic prediction of HCC patients, and can potentially act as an effective therapeutic target of HCC.
Free Hepatitis Screening Available
12 May 2018
Mon Valley Community Health Services, with Central Outreach Wellness Center, is offering a free hepatitis C screening. Hepatitis C testing requires just a finger prick to draw a drop of blood, and results are available in 15 minutes. Dr. Scott Cook, medical director at Mon Valley Community Health Services (MVCHS), said one in three people will test positive for hepatitis C. Statistic from the U.S. Department of Health and Human Services show baby boomers are five times more likely to have hepatitis C.
SMC Approves License For Liver Cancer Treatment
11 May 2018
The Scottish Medicines Consortium (SMC) has accepted Stivarga (regorafenib) as a monotherapy for the treatment of adult patients with Hepatocellular Carcinoma (HCC) who have been previously treated with Nexavar (sorafenib). Stivarga is the first medicine to be specifically licensed for second-line use in patients with HCC who had formerly been treated with sorafenib. Based on the RESORCE placebo controlled Phase III trial, patients with HCC whose disease had progressed during treatment with sorafenib showed statistically significant and clinically meaningful improvement in overall survival.
Lenvima Is Expected To Boost Merck’s Oncology Portfolio In 2018
11 May 2018
Merck, a global healthcare company, has begun a collaboration with Eisai, a Japanese based pharmaceutical company for the development and commercialization of an oral protein tyrosine kinase inhibitor, Lenvima, as a monotherapy and in combination regimens with Keytruda. Eisai submitted applications to regulatory authorities in the US, Europe, and China, seeking approval for Lenvima monotherapy in the first-line Hepatocellular Carcinoma (HCC). Lenvima secured the first worldwide approval in the unresectable HCC indication in Japan, and has become the first systemic therapy to be approved in this market for HCC in the last ten years.
Fiona Stanley Hospital Partners With ECU To Improve Outlook For Liver Disease Sufferers
7 May 2018
A new partnership between Fiona Stanley Hospital (FSH) and Edith Cowan University (ECU) hopes to improve the outlook for people with liver troubles. The iCOILD initiative will also establish national trials and strategies to prevent, rather than simply treat, liver disease. “The goal (of iCOILD – Improving Cancer Outcomes in Liver Disease) is not just mapping the prevalence of liver cancer but improving identification of those at risk and ultimately clinical trials for prevention treatment,” stated Professor John Olynyk, the lead of FSH’s Gastroenterology and Hepatology.
What’s New In Research And Treatment For Pediatric Liver Tumors?
4 May 2018
There have recently been new developments in pediatric liver tumor treatment, include more targeted therapies, while reducing the toxic effects of treatment on the body. There are two main types of liver tumors in pediatric patients, which are both very rare: hepatoblastoma and Hepatocellular Carcinoma. At Dana-Farber/Boston Children’s HCC patients have been treated with immunotherapy, a type of treatment that uses the body’s immune system to fight cancer.
Bayer’s Liver Cancer Drug Gets More Reimbursement As 2nd Line Therapy
2 May 2018
Bayer’s targeted liver cancer therapy Stivarga (regorafenib) won approval for expanded coverage as a second-line treatment. Stivarga is a once-daily, oral prescription multi-kinase inhibitor that works by blocking certain proteins on certain normal and cancer cells. Stivarga is approved to treat several diseases, including HCC, in Korea. The recent expansion covers patients who have Hepatocellular Carcinoma (HCC).
What’s The Difference?
1 May 2018
May is Hepatitis Awareness Month. According data from the Centers for Disease Control and Prevention, hepatitis, including A, B, and C, have been on the rise in recent years. There are five main forms of the disease. Although each is a little different, hepatitis is an inflammation of the liver. “Hepatitis A, B, and C are the biggest hepatitis viruses in the U.S.,” William Schaffner, MD, an infectious disease specialist and professor at the Vanderbilt University School of Medicine.
For past liver cancer news, please visit our Liver Cancer News Archives.